EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors

Komei Katayama, Nobuhisa Yoshikawa iD, Kaito Nonoyama, Satomi Hattori, Kosuke Yoshida iD, Masato Yoshihara, Satoshi Tamauchi, Akira Yokoi iD, Kaoru Niimi, Hiroaki Kajiyama

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Komei Katayama und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Sarcopenia, Immune Checkpoint Inhibitors, Endometrial Neoplasms, Muscle, Skeletal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Sarcopenia and cancer‐related muscle wasting may affect the efficacy of immune checkpoint inhibitors (ICIs). However, their prognostic significance in endometrial cancer (EC), particularly concerning skeletal muscle status at ICI initiation and pretreatment muscle change, remains unclear. We evaluated the impact of sarcopenia at ICI initiation and pre‐ICI skeletal muscle dynamics on clinical outcomes in EC.

Methods

We retrospectively analyzed 20 EC patients treated with ICIs between May 2019 and December 2024. Skeletal muscle index (SMI) was quantified using abdominal CT at the L3 level within 2 months before ICI initiation. Sarcopenia was defined as SMI < 38.5 cm 2 /m 2 . Pretreatment SMI change (ΔSMI) was calculated using baseline CT before any cancer‐directed therapy and CT immediately prior to ICI. Survival outcomes were assessed using Kaplan–Meier and Cox regression analyzes.

Results

Ten patients (50%) were sarcopenic at ICI initiation and showed a trend toward poorer progression‐free survival (PFS) and overall survival (OS). Pre‐treatment muscle loss occurred in two‐thirds of patients. Patients with decreased SMI had significantly worse OS (HR 3.64, 95% CI 1.11–11.94). In subgroup analysis, SMI decline was frequent among sarcopenic patients but did not stratify survival. In contrast, among nonsarcopenic patients, greater SMI loss was associated with poorer survival, and each 1‐unit decrease in SMI significantly worsened OS (HR 1.64, 95% CI 1.05–2.63).

Conclusions

Sarcopenia at ICI initiation and pretreatment skeletal muscle loss are potential predictors of poor prognosis in EC. Evaluating baseline muscle mass and its trajectory may improve risk stratification and help identify patients at higher risk of ICI resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcopeniaImmune Checkpoint InhibitorsEndometrial NeoplasmsMuscle, SkeletalHumansFemaleRetrospective StudiesAgedMiddle AgedPrognosisAged, 80 and over

Stichwörter der Autor:innen

endometrial neoplasmsimmune checkpoint inhibitorsmuscle wastingprognosissarcopenia

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

ORCID-Profile: Nobuhisa Yoshikawa, Kosuke Yoshida, Akira Yokoi

Zitieren

APA

Katayama, K., Yoshikawa, N., Nonoyama, K., Hattori, S., Yoshida, K., Yoshihara, M., Tamauchi, S., Yokoi, A., Niimi, K., & Kajiyama, H. (2026). Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70362

Vancouver

Katayama K, Yoshikawa N, Nonoyama K, Hattori S, Yoshida K, Yoshihara M, et al. Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70362

BibTeX
@article{Katayama2026,
  author = {Katayama, Komei and Yoshikawa, Nobuhisa and Nonoyama, Kaito and Hattori, Satomi and Yoshida, Kosuke and Yoshihara, Masato and Tamauchi, Satoshi and Yokoi, Akira and Niimi, Kaoru and Kajiyama, Hiroaki},
  title = {Impact of Sarcopenia and Pretreatment Skeletal Muscle Loss on Survival in Endometrial Cancer Patients Treated With Immune Checkpoint Inhibitors},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70362}
}
Kostenlos starten →